Portal de investigación
NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Pallares, V
- Hoyos, M
- Chillon, MC
- Conde, MIP
- Cespedes, MV
- Nomdedeu, JF
- Brunet, S
- Gonzalez-Diaz, M
- Sierra, J
- Casanova, I
- Mangues, R
Grupos
Abstract
Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients.
Datos de la publicación
- ISSN/ISSNe:
- 1949-2553, 1949-2553
- Tipo:
- Article
- Páginas:
- 76003-76014
- PubMed:
- 29100287
- Factor de Impacto:
- 1,942 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Oncotarget IMPACT JOURNALS LLC
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Keywords
- acute myeloid leukemia; nedd9; bcar1; prognostic factor; intermediate-risk
Campos de Estudio
Cita
Pallares V,Hoyos M,Chillon MC,BARRAGAN E,Conde M,LLOP M,Cespedes MV,Nomdedeu JF,Brunet S,SANZ MA,Gonzalez M,Sierra J,Casanova I,Mangues R. NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients. Oncotarget. 2017. 8. (44):p. 76003-76014. IF:5,168. (1).